CTRI/2022/09/045596尚未招募未知
Efficacy and Safety of Dapagliflozin in progression of Chronic Kidney Disease in patients with type 2 Diabetes Mellitus: A Randomised Controlled Study
Maulana Azad Medical College Delhi0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patients with diagnosis of CKD with type 2 Diabetes Mellitus with HbA1c <8% who had-
- •eGFR of 30-60ml/min/1.73m2
- •Urinary Albumin to Creatinine ratio 200-5000mg/g
- •2. Patients who are on ACE inhibitors or ARBs for at least 4 weeks before screening.
排除标准
- •1. Patients with Type 1 diabetes, lupus nephritis, Rheumatoid arthritis, Cancer and
- •Neurodegenerative disorders
- •2. Patients have received immunosuppressive therapy within 6 months.
- •3. Pregnant patients and nursing mothers.
研究者
相似试验
尚未招募
不适用
Dapagliflozin in Heart FailureCTRI/2022/11/047725Sanjay Kumar R
尚未招募
不适用
Dapagliflozin is a licensed medicine used for reducing blood sugar in people with diabetes and this study will test whether it can also reduce the stiffness in the liver which commonly occurs in diabetes.CTRI/2019/05/019286Dr Shashi Panicker
招募中
不适用
Examination of the efficacy of dapagliflozin in patients with type 2 diabetesType 2 diabetesJPRN-UMIN000021954Tonami general hospital Department of diabetes mellitus and endocrinology200
招募中
3 期
The efficacy of dapagliflozin in preventing contrast-associated acute kidney injuryAcute Coronary Syndrome.ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarctionIRCT20181026041471N1Rajaie Cardiovascular Medical and Research Institute1,500
尚未招募
2 期
Effectiveness and safety of oral dapagliflozin in reducing urinary leakage of protein in children with reduced kidney function.CTRI/2022/04/042032All India Institute of Medical Sciences